NCT07457437Recruiting
Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment
Effect of a Progressive Resistance Exercise Program on Muscle Mass and Physical Function During a Tirzepatide Induced Weight Loss in Overweight and Obese Females: a Randomised Parallel Group Study
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This study aims to investigate the effect that a structured, progressive resistance exercise program may have on maintaining the muscle mass and physical function of overweight/ obese females whilst they experience a tirzepatide (GLP-1/GIP receptor agonist) induced weight loss. Overweight and obese females aged 25-50 will be recruited for the study, they will require a BMI of \>30 or \>27 with one obesity related comorbidity (excluding diabetes). They will be screened, prescribed tirzepatide and then randomly assigned to either the intervention (GLP-1/GIP + Exercise) or the control group (GLP-1/GIP). Groups will then be split into pre and peri menopausal groups to provide a further exploratory pathway looking analysing if the menopause transition may have any effect on our outcome variables. This was proposed as in the UK females are more likely to begin GLP-1RA treatment. Both groups will be given an industry standard treatment of tirzepatide over 20 weeks starting at a dose of 2.5mg/week and following the dose titration process of +2.5mg/week every four weeks outlined by its manufacturers. The Exercise Group (GLP-1 +EXC) will be given the same tirzepatide prescription alongside following a progressive resistance exercise program. The exercise program will follow a similar structure to previous work in which participants will complete a propriety 20-wk whole body, low impact resistance exercise training program four times a week. The exercise sessions will be up to an hour and will be instructor lead by video and supervised by a member of the research team at The University of Exeter.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of Exeter
- Diseases
- Obesity
- NCT number
- NCT07457437
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 1 Apr 2026 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous GLP-1RA use
- Has or has previously had an eating disorder
- Has consistently resistance trained previously (\>10 sessions per year)
- Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months
- Currently on HRT
Other illness
- Diabetes (Type 1 and 2)
- Contraindicative health condition to GLP-1/GIP
Other
- Fail clinically administered health screening form for tirzepatide prescription
- Pregnant or wanting to become pregnant in the next 6 months
- Inability to perform exercise program and exercise tests
- Advised not to exercise by their general practitioner or medical professional
- Current or recent injury within the last 6 months that may affect the ability to carry out resistance exercise
- Current or recent, ≤6 months, smoker
Who the study is looking for
- 25-50 years old
- BMI ≥27 kg/m2 with one obesity related co-morbidity or a BMI between ≥30 and 35 kg/m2
- Female
Age in the registry: 25 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nutritional Physiology Research Unit Coordinator of this site? Confirm its status | Exeter | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.